Evaluation of optimal timing and therapeutic efficacy of radium-223 therapy for metastatic castration-resistant prostate cancer: a multicenter collaborative study.
Urabe F, Kadena S, Tashiro K, Tokuoka K, Taneda Y, Fujiwara K, Goto Y, Nakano J, Kawano S, Iwamoto Y, Fukuokaya W, Imai Y, Iwatani K, Atsuta M, Ito K, Yanagisawa T, Murakami M, Tsuzuki S, Yamamoto T, Shimomura T, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group.
Urabe F, et al. Among authors: imai y.
Jpn J Clin Oncol. 2025 Jan 17:hyaf007. doi: 10.1093/jjco/hyaf007. Online ahead of print.
Jpn J Clin Oncol. 2025.
PMID: 39820640